31 results
424B5
TCRX
Tscan Therapeutics Inc
17 Apr 24
Prospectus supplement for primary offering
9:58pm
Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about
8-K
EX-1.1
TCRX
Tscan Therapeutics Inc
17 Apr 24
TScan Therapeutics Announces Launch of $125 million Proposed
6:25am
, policies and procedures, including oversight, access controls, encryption, technological and physical safeguards and business continuity/disaster … thereunder adopted by the Commission and the Public Company Accounting Oversight Board (United States).
(kk)
The Company and its subsidiaries, taken
424B5
TCRX
Tscan Therapeutics Inc
16 Apr 24
Prospectus supplement for primary offering
5:21pm
Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about
8-K
EX-99.1
1xe94f md
8 Apr 24
TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert
8:17am
8-K
EX-1.1
j6lpmos ug
31 May 23
TScan Therapeutics Announces Launch of Proposed Public Offering
8:16am
424B5
kkikwz0hz55he
26 May 23
Prospectus supplement for primary offering
8:12pm
424B5
dnnof
25 May 23
Prospectus supplement for primary offering
4:59pm
8-K
EX-1.1
2w0s3g
16 May 23
Other Events
5:21pm